TransCode (RNAZ) news
Recent news
ImportantTransCode Therapeutics stock slides nearly 57% after pricing stock offering to raise $3 million
TransCode Therapeutics stock slides nearly 57% after pricing stock offering to raise $3 million TransCode Therapeutics, Inc. (RNAZ), a clinical-stage RNA oncology company, announced on July 22, 2024, the pricing of a public offering of 10 million shares of its common stock at $0.30 per share [1].…
AInvest Wire · Jul 23, 2024TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering TransCode Therapeutics, an RNA oncology company, recently announced the closing of a public offering of its common stock and warrants, raising gross proceeds of $7.25 million [1]. The offering consisted of 5,942,623 shares of…
AInvest Wire · Jan 22, 2024TransCode Therapeutics surges 40% after withdrawing public offering
AInvest Wire · Oct 31, 2023TransCode Therapeutics shares slide 25% in premarket trading on public offering of common stock.
AInvest Wire · Oct 27, 2023ImportantTransCode Therapeutics Up 9.4% After CEO and CFO Report Stock Purchases
AInvest Wire · Oct 3, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.